top of page


Peder Holk Nielsen
Former CEO of Novozymes

Non-Executive Director 

Peder was the President/CEO of Novozymes for 7 years from 2013 to 2020. In total he spent 35 years at Novozymes, 25 of which on the executive board. During this time he shaped the business strategy and culture into the global company it is today. 

Untitled design (91).png
Untitled design (92).png

Leopoldo Zambeletti
Former Head of Healthcare JP Morgan

Non-Executive Director 

Leopoldo led the European Healthcare Investment Banking team at JP Morgan for eight years before taking up the same position at Credit Suisse for a further five years. Since 2013, Leopoldo has been an independent strategic advisor to life science companies on mergers and acquisitions, out-licencing deals, and financing strategies. Leopoldo is a Non- Executive Director of Philogen, Nogra Pharma and The Meatless Farm.

Victoria Van Lennep
Co-founder of Lendable 

Victoria is a co-founder of Lendable, one of Europe’s fastest-growing unicorns, currently valued at £3.5Bn. Her experience developing proprietary AI to disrupt fintech resonates with Bactobio's focus on AI-driven drug discovery and crop protection. 

Martin Kissinger, Paul Pamment and Jakob Schwarz, co-founders of Lendable, are also current investors.

Together, they bring a wealth of unique entrepreneurial experiences in navigating the evolution of a start-up from infancy to a multibillion-dollar company.         


Non-Executive Director 


Bridford Group

Bridford Group is an investment group which deploys its permanent proprietary capital in a range of sectors, including music, tech, sustainability, lifestyle and biotech. The group’s focus is on backing founder-led businesses with long-term growth potential, ideally those which promote societal or environmental welfare. 

Hugh Grant
Last CEO of Monsanto 

Hugh was Chairman and CEO of Monsanto for 15 years until the $66 Billion sale to Bayer in 2018. During this time, Hugh successfully led the strategic transformation from a chemical company to a global seed and technology pioneer through strong R&D investment and over 70 strategic M&A transactions. He has been recognised globally as a leader in business and Life Sciences, renowned for his emphasis on innovation.

Lord David Prior
Chairman of NHS

David is the current Chair of the English National Health Service. David was elected MP for North Norfolk in 1997. In 2015, David was appointed Parliamentary Under Secretary of State for Health and created a Life Peer.

Dr Jonathan Milner
Founder of Abcam

 Jonathan is the principal founder and former CEO of Abcam. After building Abcam from scratch to a multinational company with a market cap of £3 bn, Jonathan stepped down to focus on his activity as an angel investor and advisor. Jonathan brings a wealth of industry experience in bio-derived chemicals and unique entrepreneurial experience from having built a deep tech company into a unicorn.

Claudio Castamagna
Former CEO of Goldman Sachs Europe

Claudio sits on the board of FTI Consulting. Previously, Claudio was the Chairman of AAA-Advanced Accelerator Applications when it was acquired by Novartis for $3.9 Bn in 2018. Mr. Costamagna worked in various positions within The Goldman Sachs Group, culminating as Chairman of the investment banking division for Europe, The Middle East and Africa (EMEA).

Dr David Hughes
Former Head of Anti-infectives Novartis 

 David is currently Head of Clinical Development for Biopharmaceuticals at Sandoz AG, having previously held the role of Senior Global Program Head - Anti-infectives at Novartis and worked in managerial roles for Pfizer and McKinsey. David is a board-certified physician with an MD from the University of Toronto and an MPH from Johns Hopkins University.

Funding Support

image (6).png

Ludwig Maximilian University of Munich

We are extremely grateful for our laboratory space at the LMU in Munich, which allowed us to get our research off the ground.

image (7).png
image (8).png

Exist- Grunderstipendium

Our first round of funding came in the form of a EXIST-Grunderstipendium, which enabled us to conduct a wealth of proof-of-concept experiments.

image (9).png

Innovate UK

We have been incredibly fortunate to benefit from four grants from Innovate UK, the UK's innovation agency. We're using these funds to accelerate the discovery of new antibiotics and fungicides.

bottom of page